ResearcherOncotab, IncActive in the last 2 years

Ru zhou

Verified by NIH RePORTER profile ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on NIH RePORTER profile ID 12535288. Sources: NIH RePORTER.

Their work

Papers: 0
Trials: 0
Grants: 4
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2021: 2 grants · 2022: none · 2023: none · 2024: none · 2025: 1 grant · 2026: 1 grant

Grants 4

Combination Therapy of T-Cell Engager and Chemotherapy for Pancreatic Cancer Treatment R44CA306447 ↗
Optimized targeted radiotherapy of pancreatic cancer R41CA284997 ↗
The use of tMUC1/CD3 bispecific antibody to control pancreatic ductal adenocarcinoma R41CA265619 ↗
An integrated strategy using a serum and imaging biomarker for the early detection of pancreatic cancer. R41CA265655 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Pinku Mukherjee · 4 shared grants, 2021–2026 · strength 3.19
Rahul Puri · 1 shared grant, 2026 · strength 1.00
- Grant Combination Therapy of T-Cell Engager and Chemotherapy for Pancreatic Cancer Treatment R44CA306447 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.